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The comparison of the KRB values before and after
splenectomy and splenorenal shunt showed individual
variations mainly when the values of KBB after surgery
are obtained shortly after the operation. In all the patients
studied for periods longer than 3 months, and in whom
there was a decrease in KRB at first determination a short
time after surgery, an increase in KRB values was later
observed.
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The Use of Antimalarial Drugs
C. F. HANSFORD
SUMMARY
A general review is given of the antimalarial drugs cur-
rently available and in common use, with special reference
to those found to be of most benefit in Southern Africa.
S. Afr. Med. J., 48, 1314 (1974~
LIFE CYCLE OF THE PARASITE
Before discussing the action of antimalarial drugs some
aspects of the malaria parasite cycle should be considered.
The parasite is inoculated by the mosquito as the sporo-
zoite form, which within an hour enters liver cells
and commences growth and subdivision, forming primary
exo-erythrocytic or pre-erythrocytic schizonts. After a few
days these schizonts mature and rupture,- each releasing
hundreds of merozoites which invade circulating red blood
cells. In Plasmodium vivax, malariae and ovale infections
some of these merozoites also enter liver cells, starting a
new cycle of exo-erythrocytic division called secondary
exo-erythrocytic schizogony_ This stage is responsible for
the late relapses associated with these species of parasite.
It does not occur in P. falciparum infections.
In fue red blood cells the parasites become trophozoites,
take 2 - 3 days to develop, divide and form mature
schizonts which rupture, forming merozoites which in
turn invade further red blood cells. The breaking-up of the
mature schizonts releases products responsible for the
pyrexial attacks typical of malaria. A few trophozoites do
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not form schizonts but develop into male and female
garnetocytes. These may continue to circulate for periods
up to a month unless they are ingested by suitable mos-
quitoes in which fuey mate, develop further and sub-
divide, forming sporozoites which migrate to the salivary
glands.
Individual antimalarial drugs do not have a similar
action against all stages of malaria parasites, nor against
all 4 species of human malaria, and this fact must be
taken into consideration when drugs are prescribed for
prophylaxis, cure or gametocidal purposes.
CLASSIFICATION OF ANTIMALARIAL
DRUGS
Antimalarial drugs are commonly classified by their chemi-
cal characteristics and by their site of action on the
parasite.
Aminoquinoline Drugs
Basically these have a benzene and a pyridine ring fused
together and are divided into 4- and 8-aminoquinolines,
depending on the position of the side chain. J"he 4-amino-
quinoline drugs include chloroquine and amodiaquine, the
most important of present antimalarial drugs. They have
a low toxity, are highly effective against the asexual blood
trophozoite and for these reasons are the drugs of choice
in the treatment of the acute attack. Unfortunately they
have no action against any other stage of the parasite.
They are rapidly absorbed, slowly metabolised and ex-
creted, necessitating the use of a loading dose at the
commencement of treatment. At the oral dosages nor-
mally employed, toxic effects are minor, usually cmisisting
of nausea, headaches and dizziness, but care must be
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The only 8-aminoquinoline of importance is primaquine
which is effective against virtually all stages of malaria.
Unfortunately it is too toxic for general use, particularly
among individual> with glucose-6-phosphate dehydroge-
nase deficiency, and for this reason is only used under
close supervision, against secondary exo-erythrocytic forms
of P. vivax, malariae and ovale infections, to ensure
radical cure.
Folic Reductase Inhibitors
These drugs inhibit enzymes involved in the formation
of folic acid and include proguanil and pyrimethamine
which are effective against the primary exo-erythrocytic
forms of P. falciparum. Unfortunately in Southern Africa
some strains of P. falciparum have developed resistance
to these drugs, which should now only be used for pro-
phylaxis in combination with other antimalarials. Inject-
able derivatives of these drugs have not given reliable
protection.
The action of these drugs against circulating blood
schizonts is too slow to warrant their use alone. They also
prevent the further development of gametocytes in the
mosquito and may be administered for this purpose.
Quinine
Quinine has a rapid action against asexual circulating
parasites and is now principally used for the parenteral
treatment of severe P. falciparum infections. It is also
effective against the gametocytes of P. vivax and ovale. It
is rapidly absorbed and excreted. A dose of 650 mg of the
dihydrochloride may be slowly given intravenously and
may be repeated once or at most twice in 24 hours. In
children the daily parenteral dose should not exceed 20
mg/kg.
Sulphones and Sulphonamides
These drugs are effective against the circulating asexual
forms of P. falciparum, but are not sufficiently active to
warrant their use for curative purposes except in combina-
tion with other antimalarials. When used in combination
with pyrimethamine or trimethoprim their action is poten-
tiated and dosages may be reduced.
Side-effects may prove troublesome and their widespread
use may induce resistance in malaria as well as in other
organisms such as meningoccoci. They may become pro-
tein-bound in some individuals and ineffective against
malaria parasites.
Experience gained over the next few years will deter-
mine the position of these drugs for prophylaxis and
treatment.
Other Drugs
Mepacrine is highly effective against asexual circulating
parasites but on account of toxicity has been replaced by
4-aminoquinoline drugs.
Tetracyclines possess a slow antimalarial action and are
used in combination with other drugs for the treatment
of drug-resistant infections.
The diagnosis of malaria may be obscured when drugs
such as sulphonamides, tetracyclines and trimethoprim
with antimalaria activity have already been administered
to the patient. These drugs may cure or alleviate malaria
infections, depending on the severity of infection and host
reaction, resulting in a missed infection or a later relapse.
RECOMMENDED USE OF DRUGS
Prophylaxis
Prophylaxis should take place at the earliest possible
stage of the parasite in man. Pyrimethamine and proguanil
are the best drugs in this respect, since they are effective
against the pre-erythrocytic stages of P. falciparum, the
commonest malaria species. Unfortunately in many parts
of Africa P. falciparum has developed a resistance to these
drugs, which by themselves cannot now be relied upon
to give complete prophylaxis. To overcome this difficulty
they may be used in combination with sulphones and
sulphonamides, but more experience is required to assess
their efficiency and the incidence of side-effects. Proguanil
and pyrimethamine should not be given alone for pro-
phylaxis.
Drugs acting against the -asexual circulating stages of
malaria parasites can also be used as suppressive prophy-
lactics. Chloroquine or amodiaquine are recommended
for this purpose, but the question· is frequently raised of
the desirability of using the same drug for treatment as
for prophylaxis. Strains of chloroquine-resistant P. falci-
pat·um have developed in South-east Asia and in South
America but not in Africa, where it has been shown that
the local P. falciparum strain is basically more sensitive
to chloroquine than elsewhere. For this reason and on
account of their low toxicity, 4-aminoquinolines (chloro-
quine and amodiaquine) have been recommended as the
most dependable prophylactics for African conditions and
thus must be advised for individual prophylaxis. They
should be administered immediately before, during, and
for 4 weeks after the last exposure to malaria to allow pre-
erythrocytic stages to mature and be eliminated when they
develop in the circulating blood. This 4-weeks' prophylaxis
after exposure to malaria is most important and failure to
continue prophylaxis for this period is responsible for many
malaria infections.
A combination of pyrimethamine or proguanil and a
4-aminoquinoline may be used for prophylaxis to obtain
the benefit of the former's action against the early stages
of the parasite and the latter's action against resistant
parasites which may reach the circulating blood.
The Department of Health recommendation for prophy-
laxis in adults is a weekly dose of 300 mg base of chloro-
quine or amodiaquine to be taken for the duration of the
period of exposure and for the following 4 weeks.
Pyrimethamine 25 mg weekly or proguanil 100 mg daily
may be given in addition.
The danger of exposure to species of malaria other
than P. falciparum may be ignored in South Africa, but
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where it is present the additional use of primaquine after
exposure should be considered to eliminate secondary exo-
erythrocytic parasites and the possibility of prolonged pre-
patent infections.
TREATMENT
Dosage recommendations for treatment vary with the
immune status and defense mechanism of the host, sur-
prisingly small dosages being required for curing infected
semi-irnrnunes. In South Africa where malaria transmis-
sion is low, all hosts must be considered non-immune and
treated accordingly.
The 4-aminoquinoline drugs are the basis of treatment
on account of their rapid action against asexual circulating
parasites and low toxicity. CWoroquine or amodiaquine
should be given in divided doses of 900 mg base on day 1
and 300 mg on day 2 and on day 3. The initial doses
should be given parenterally where vomiting is present
or the illness is severe. A total daily parenteral adult dose
of 900 mg base should not be exceeded and individual
doses should not exceed 300 mg base (normally 10 ml of
5% solution). This standard treatment will be sufficient
for the majority of infections but occasionally a higher
total dosage may be required, possibly on account of
variable host responses. Quinine may be used in addition
for fulminating infections. This treatment will give a
radical cure for P. falciparum infections but not for other
malaria species, when primaquine should also be given in
an adult dosage of 15 mg base daily for 14 days.
Drug treatment is only part of the management of
malaria infections; the control of electrolyte balance, cir-
culatory disturbances, renal failure, etc. are equally im-
portant.
When the patient is returning to potentially malarious
areas 50 mg of pyrimethamine should also be given to
sterilise gametocytes and prevent their further develop-
ment in the mosquito. If this is not undertaken, the
patient, although clinically cured, may still be infectious to
the mosquito and be responsible for a further focus of
malaria transmission.
As a public health measure a single dose of 600 mg
cWoroquine combined with 60 mg pyrimethamine is given
for presumed asymptomatic infections awaiting confirma-
tion by blood examination. This cures the majority of
infections among semi-immune hosts, but a full treatment
is given on confirmation of the infection.
In South-east Asia, where cWoroquine-resistant P. falci-
parum infections are common, treatment consists of a
combination of two or more antimalarial drugs. The re-
sponse to these drugs varies with different strains of
parasite and local knowledge is useful for recommending
prophylaxis and treatment.
In conclusion I would like to emphasise again that in
Southern Africa pyrimethamine alone cannot be relied
upon for prophylaxis - cWoroquine should be the basis
of prophylaxis and treatment.
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